Orospray

Pays: Irlande

Langue: anglais

Source: HPRA (Health Products Regulatory Authority)

Ingrédients actifs:

Chlortetracycline; Sulphanilamide

Disponible depuis:

Vetoquinol Ireland Limited

Code ATC:

QD06AA52

DCI (Dénomination commune internationale):

Chlortetracycline; Sulphanilamide

Dosage:

2.85, 50 gram/100gram

forme pharmaceutique:

Cutaneous spray, powder

Type d'ordonnance:

POM: Prescription Only Medicine as defined in relevant national legislation

Groupe thérapeutique:

Cattle, Dogs, Goats, Horses, Sheep

Domaine thérapeutique:

chlortetracycline, combinations

indications thérapeutiques:

Antibacterial

Statut de autorisation:

Authorised

Date de l'autorisation:

1988-10-11

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Orospray
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous spray, powder.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses, Cattle, Goat, Sheep and Dog.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the topical treatment of wounds infected by organisms sensitive to
the active ingredients.
For the prevention and treatment of post operative infections
following surgical procedures by topical application.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to one of the
ingredients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Each 100g powder contains :
Active substances:
Chlortetracycline (as hydrochloride) 2.850
g
Sulfanilamide
50.000 g
Excipients:
Methyl parahydroxybenzoate
0.115
g
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_4_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_6_
_0_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTION(S) FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing of the
bacteria isolated from the animal. If this is not possible,
therapy should be based on local (regional, farm level)
epidemiological information about susceptibility of the target
bacteria.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
MEDICINAL PRODUCT TO ANIMALS
Pressurised co